

1 **IL-6 inhibition in critically ill COVID-19 patients is associated with**  
2 **increased secondary infections**

3  
4 Lucas M. Kimmig<sup>1,2\*</sup>, David Wu<sup>1,2,\*</sup>, Matthew Gold<sup>1</sup>, Natasha N Pettit<sup>1,3</sup>, David Pitrak, MD<sup>1,3</sup>,  
5 Jeffery Mueller<sup>4</sup>, Aliya N. Husain<sup>4</sup>, Ece A. Mutlu<sup>5</sup> and Gökhan M. Mutlu<sup>1,2</sup>  
6

7 <sup>1</sup>Department of Medicine, <sup>2</sup>Section of Pulmonary and Critical Care Medicine and <sup>3</sup>Section of  
8 Infectious Diseases and <sup>4</sup>Department of Pathology, University of Chicago, Chicago, Illinois, and  
9 <sup>5</sup>Section of Gastroenterology and Hepatology, Rush University, Chicago, Illinois  
10

11 \*Equal contribution  
12

13 Running title: IL-6 inhibition increases bacterial infections  
14

15 Corresponding author:

16 Gökhan M. Mutlu, MD  
17 Section of Pulmonary and Critical Care Medicine  
18 University of Chicago  
19 5841 S Maryland Ave  
20 MC6026  
21 Chicago, IL 60637  
22 Phone: 773-702-1002  
23 Fax: 773-702-6500  
24 Email: [gmutlu@medicine.bsd.uchicago.edu](mailto:gmutlu@medicine.bsd.uchicago.edu)  
25

26 **Keywords: COVID-19, SARS-CoV-2, tocilizumab, cytokine release syndrome,**  
27 **immunosuppression**  
28  
29

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

### 30 **ABSTRACT**

31 **Background:** Anti-inflammatory therapies such as IL-6 inhibition have been proposed for  
32 COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory  
33 response in infectious diseases may impair a desired host response and predispose to secondary  
34 infections.

35 **Methods:** We retrospectively reviewed the medical record of critically ill COVID-19 patients  
36 during an 8-week span and compared the prevalence of secondary infection and outcomes in  
37 patients who did and did not receive tocilizumab. Additionally, we included representative  
38 histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at  
39 our institution.

40 **Results:** 111 patients were identified, of which 54 had received tocilizumab while 57 had not.  
41 Receiving tocilizumab was associated with a higher risk of secondary bacterial (48.1% vs.  
42 28.1%,  $p=0.029$  and fungal (5.6% vs. 0%,  $p=0.112$ ) infections. Consistent with higher number of  
43 infections, patients who received tocilizumab had higher mortality (35.2% vs. 19.3%,  $p=0.020$ ).  
44 Seven cases underwent autopsy. In 3 cases who received tocilizumab, there was evidence of  
45 pneumonia on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence  
46 of aspiration pneumonia and 2 exhibited diffuse alveolar damage.

47 **Conclusions:** Experimental therapies are currently being applied to COVID-19 outside of  
48 clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair  
49 viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician  
50 awareness of these issues and highlight the need to better understand the immune response in  
51 COVID-19.

## **IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections**

### **52 1 INTRODUCTION**

53 While there has been a dramatic increase in the number of clinical trials, there remains a shortage  
54 of effective therapies for COVID-19, particularly for patients who develop critical illness. The  
55 management of such patients remains largely supportive. Early reports from China suggested  
56 that an exaggerated immune response may play a role in the development of respiratory failure,  
57 shock, and multiorgan dysfunction in critically ill patients with COVID-19 (1). Similarities  
58 between the exaggerated immune response associated with COVID-19 and the cytokine release  
59 syndrome (CRS) reported in patients with CAR T-cell therapy led to the use of tocilizumab, an  
60 anti-IL-6 therapy to attenuate hyperimmune responses associated with COVID-19 (2). However,  
61 inhibition of IL-6 may also have adverse consequences. Mice lacking IL-6 response have  
62 impaired immunity against viral, bacterial and fungal pathogens (3). Humans treated with  
63 tocilizumab had higher risk of serious bacterial, skin and soft tissue infections (4-7). Lastly, IL-6  
64 appears to play a complicated role viral clearance(8). To date, several reports detail institutional  
65 experiences with treating COVID-19 with tocilizumab.(9-13) As expected, inflammatory  
66 markers (cytokines, temperature) generally demonstrated a profound response to tocilizumab  
67 administration. However, as most reports lack a comparison group, it is difficult to ascertain  
68 whether patients clinically benefitted from inhibition of the inflammatory response. Similarly,  
69 available reports often restrict secondary infections to documented blood stream infections,  
70 which may significantly underestimate the infectious complications of anti-IL-6 therapy in the  
71 critically ill. We sought to determine the incidence of secondary infections and outcomes of  
72 patients who received tocilizumab for COVID-19 compared to those who did not in the COVID-  
73 19 intensive care unit (ICU) at our institution.

### **74 2 METHODS**

#### **75 2.1 Patients**

76 We retrospectively analyzed all patients who were admitted to the COVID-19 ICU between the  
77 dates of March 1, 2020 and April 27, 2020. The study was approved by the University of  
78 Chicago Institutional Review Board. Additionally, 7 patients underwent autopsy, the  
79 histopathology of which was reviewed with our colleagues from pathology.

#### **80 2.2 Interventions**

81 Tocilizumab was included in our internal institutional protocol for the treatment of COVID-19,  
82 specifically for use in patients with progressive clinical deterioration and elevated inflammatory  
83 markers at the discretion of the treating team and infectious diseases consultation service. Our  
84 protocol recommended a standard dose of 400 mg of tocilizumab administered intravenously  
85 with the potential for redosing based on clinical response (e.g. oxygenation status, hemodynamic  
86 stability, inflammatory marker response). Tocilizumab was generally not considered in patients  
87 with liver function test (LFT) abnormalities, significant cytopenias, or documented ongoing  
88 infection. Similarly, patients enrolled in clinical trials (e.g. remdesivir) were not eligible to  
89 receive tocilizumab.

#### **90 2.3 Statistical Analysis**

91 Statistical analysis was conducted with SPSS version 26 (IBM, Armonk, NY) and R version 4  
92 (Package Logistf). APACHE II score and Charlson comorbidity index (CCI) were not normally  
93 distributed and thus were analyzed with Mann-Whitney U-test. Count variables were analyzed  
94 with Chi-square and continuous variables were analyzed with t-tests.

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

95 Multivariate regression analysis was completed in R with the outcome variable being the  
96 development of bacterial infection. The predictors (i.e., independent variables) were selected  
97 using Chi-square statistics. Variables that are statistically different between those were given  
98 tocilizumab and those who were not, were sex with the predominance of males in the  
99 tocilizumab group, history of transplant and use of immunosuppressive agents, and APACHE II  
100 scores were trending higher in the tocilizumab group ( $p=0.078$ , Mann-Whitney U test) (see table  
101 1). There was high correlation between history of transplantation and immunosuppressive use as  
102 expected. Thus, we only included immunosuppressive use in the multivariate model. There was a  
103 trend towards a higher proportion of patients with diabetes mellitus with organ damage in those  
104 with bacterial infection and past medical history of deep venous thrombosis (DVT) or pulmonary  
105 embolism (PE). No other clinical variables were statistically different by tocilizumab use or the  
106 development of bacterial infections. Although steroid use was not statistically significantly  
107 different between those were given tocilizumab and those who were not, steroids were included  
108 in the model as they have been shown to affect COVID19 disease course and can predispose to  
109 bacterial infections. Therefore, the final model included age, sex, tocilizumab use, steroid use,  
110 diabetes with organ damage, DVT/PE, CCI, APACHE II score and immunosuppressive use. Of  
111 these, age, sex, diabetes with organ damage, CCI, and immunosuppressive use were not  
112 independently associated with the development of bacterial infections (all  $p>0.05$ ). The reported  
113 odds ratios (ORs) reflect exponents of  $\beta$  from a Firth penalized regression model in R. Firth  
114 regression was chosen to avoid separation in the model (14).

### 115 3 RESULTS

116 **Bacterial infections are increased in critically ill patients who received tocilizumab.** We  
117 identified 111 patients admitted to the COVID-19 ICU during that period. Among 54 patients  
118 who received tocilizumab, the majority (44 patients, 81%) received the standard dose of 400 mg.  
119 However, protocol deviations occurred with respect to dosing in some patients. Six patients  
120 received a total of 800 mg, one patient received 560 mg, two patients received 200 mg and one  
121 patient received 160 mg. We compared bacterial and fungal infections in those that received the  
122 drug to those that did not. Except for the male sex preponderance in tocilizumab group, there  
123 were no differences in patient baseline characteristics including CCI between the two groups  
124 (Table 1). Secondary infections were defined by positive culture data or high clinical suspicion  
125 of infection requiring the initiation of antimicrobials and documentation in the progress note. In  
126 the tocilizumab group, only infections occurring after the tocilizumab dose were counted.

127 Receiving tocilizumab was associated with a higher incidence of secondary bacterial infections  
128 including hospital acquired pneumonia and ventilator associated pneumonia (26 (48.1%) vs. 16  
129 (28.1%).  $p=0.021$ ). Additionally, there were three patients with fungal infections with one patient  
130 having the fungal infection in two different locations in the tocilizumab group compared with  
131 none in the non-tocilizumab group with statistical analysis showing a trend towards significance  
132 ( $p=0.112$ ). Diagnosis of infection was made approximately 5 days after the administration of  
133 tocilizumab ( $4.9\pm 3.0$  days, median=4 days, 95% CI 3.67-6.17 days).

134 **Tocilizumab is independently associated with increased bacterial infections.** In multivariate  
135 logistic regression model to predict bacterial infections, the following independent variables  
136 were included: age, sex, APACHE II score, CCI, immunosuppression, presence of DVT/PE,  
137 diabetes with any organ damage and use of tocilizumab and steroids. Tocilizumab use was  
138 independently positively associated with the development of bacterial infections with an odds

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

139 ratio of 2.76 (95% CI 1.11-7.20)  $p=0.0295$ . APACHE II score was also independently positively  
140 associated with bacterial infections (OR: 1.08, 95% CI: 1.01-1.16,  $p=0.016$ ). While steroid  
141 administration did not reach statistical significance, there was a trend towards steroids being  
142 positively associated with bacterial infections (OR: 2.76, 95% CI: 0.91-9.02,  $p=0.074$ ). History  
143 of DVT/PE was negatively associated with bacterial infections (OR: 0.09, 95% CI: 0.0007-  
144 0.824). The remaining variables including age, sex, CCI, immunosuppression, and presence of  
145 diabetes with any organ damage were not independently associated with bacterial infections.

146 Due to well-known limitations with bacterial cultures in hospitalized and critically ill patients,  
147 we included both culture-proven and suspected bacterial infections in our analysis. While the  
148 tocilizumab group had 10 culture proven bacterial infections, non-tocilizumab group had 9  
149 culture proven bacterial infections. This was not statistically significant. Seven patients in the  
150 non-tocilizumab and 16 patients in the tocilizumab group were treated for a bacterial infection  
151 although the cultures were negative or non-diagnostic. There was no statistical difference  
152 between the two groups in terms of culture negative bacterial infections ( $p=0.261$ ).

153 We also compared laboratory data between two groups. In addition to the laboratory data  
154 included in the APACHE II score, we analyzed white blood cell count (WBC), percent and  
155 absolute lymphocyte count, D-dimer, C-reactive protein and ferritin, which were evaluated to  
156 determine the level of systemic inflammation as part of laboratory work up for COVID-19.  
157 There was no difference in WBC, percent lymphocyte, D-dimer, C-reactive protein and ferritin  
158 levels between the tocilizumab and non-tocilizumab groups (Figure 1). However, mean absolute  
159 lymphocyte count was statistically lower in tocilizumab group compared to non-tocilizumab  
160 group (mean difference =0.33,  $p=0.02$ ). However, there was no correlation between bacterial  
161 infections and the absolute lymphocyte count (Spearman's  $\rho = -0.005$ ,  $p=0.959$ ). Inclusion of  
162 the absolute lymphocyte count in the multivariate Firth regression did not change the significant  
163 variables in the model (data not shown).

164 Our study did not follow outpatient status of patients treated in the ICU and not all patients had a  
165 definite outcome at the time of the study. In this preliminary analysis, compared to patients who  
166 did not receive tocilizumab, those who were prescribed tocilizumab had higher mortality (19/54  
167 (35.2%) vs. 11/57 (19.3%,  $p=0.020$ ) and a lesser number of patients were discharged home in the  
168 tocilizumab group (33.3% vs. 59.6%, tocilizumab and non-tocilizumab group, respectively)  
169 (Table 2).

170 All 5 transplant patients in the study received tocilizumab. Out of these 5 patients, two were  
171 treated for a bacterial infection (one culture proven, and the other presumed based on high  
172 clinical suspicion of infection). Only one of the patients in the transplant group died. Overall  
173 transplant status did not affect outcomes. We also reviewed the administration of steroids and  
174 other immunosuppressive agents. More patients in the tocilizumab group received steroids  
175 compared to non-tocilizumab group (8 (14%) vs. 13 (24.1%),  $p=0.227$ ). Administration of  
176 immunosuppressive agents, steroids alone or in combination with tocilizumab did not affect the  
177 outcomes (Table 2). After exclusion of immunosuppressed individuals from the dataset, a higher  
178 proportion of patients with bacterial infections were still observed in the tocilizumab group  
179 (16/57 vs. 24/49,  $p=0.034$ ).

180 **Postmortem evaluation of cases.** We performed post-mortem evaluation of 7 cases; 3 received  
181 tocilizumab and 4 did not. All three cases who received tocilizumab had evidence of pneumonia  
182 on pathology (Figure 2). Two of four patients who did not receive tocilizumab were nursing

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

183 home residents with history of stroke and dementia and they died on the same day of admission.  
184 Their post-mortem evaluation showed evidence of aspiration pneumonia. The other two patients  
185 who did not receive tocilizumab were hospitalized for 4 and 12 days. Their lungs demonstrated  
186 only pathological changes consistent with diffuse alveolar damage without any evidence of  
187 pneumonia (Figure 2). These findings raise concerns about the use of tocilizumab to attenuate  
188 possible CRS. In particular, the occurrence of secondary bacterial infections may prolong ICU  
189 stays, and the occurrence of secondary fungal infections stands out as unusual in critical care  
190 patients without traditional risk factors (e.g. neutropenia).

### 191 4 DISCUSSION

192 Receiving tocilizumab was associated with a significantly higher rate of secondary infections and  
193 mortality at our institution. Furthermore, review of the available autopsy findings suggest that  
194 bacterial pneumonia is not uncommon in patients who die from COVID-19, particularly if they  
195 have received tocilizumab previously. These findings raise concerns about the use of anti-IL-6  
196 therapy to attenuate a cytokine-release-like syndrome in COVID-19.

197 Host response to the pathogen during sepsis is a double-edged sword. Infection is generally met  
198 by a desired host inflammatory response, which can at times be vigorous. For decades,  
199 physicians have speculated whether this host response is to blame, at least in part, for the multi-  
200 organ dysfunction associated with infection, as can be seen in sepsis. In fact, the most recent  
201 definition of sepsis includes the term “dysregulated host response to infection”. According to  
202 current thought, there is orchestration of temporally distinct phases of the immune response,  
203 consisting of both initial prompt upregulation and subsequent curtailment. Dysfunctional  
204 responses may lead to overwhelming infection or persistent inflammation. Cytokines must be  
205 viewed through this lens: IL-6 may contribute to organ injury and death, but it is also central to  
206 innate immunity and microbial clearance.

207 At this time, it remains difficult to characterize the stage of the inflammatory response on an  
208 individual basis in real time. Similarly, many characteristics seen in severe inflammation,  
209 including, within autoregulatory limits, hypotension, may in fact represent an adaptive response.  
210 A dramatic elevation in inflammatory cytokines or other markers such as ferritin may indicate a  
211 particularly brisk host response against a more severe infection. Without proper discriminatory  
212 values that reliably identify patients in whom hyper-inflammation is the key driver of  
213 pathogenesis, treatment with anti-inflammatory therapies may be detrimental. While there may  
214 be a subset of patients who may potentially benefit from the use of tocilizumab, current evidence  
215 does not support the routine use of tocilizumab or other drugs that regulate host immune  
216 response (i.e. anti-IL1, anti-TNF $\alpha$ ) in COVID-19 or non-COVID-19 sepsis. Evidence of efficacy  
217 for IL-6 blockade currently exists in rheumatological diseases and to manage complications of T  
218 cell engaging therapies, which are driven by a primary immune response. To date, there is no  
219 convincing evidence that immune blockade is clinically beneficial when microbial infections  
220 drive the host response. Indeed, a previous anti-cytokine strategy targeting TNF $\alpha$  increased  
221 mortality in septic patients (15) and was linked to increased risk of infections(16).

222 There are several important limitations to our study. The most important limitation is the  
223 retrospective nature and lack of randomization. Naturally, this does not allow for the  
224 establishment of causality. Because our study was retrospective, while the majority of baseline  
225 characteristics were similar, there were some that were slightly different. These include the  
226 history of transplant and use of immunosuppressive agents. Despite these limitations, patients in

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

227 both groups were relatively closely matched with regards to severity of illness (APACHE II  
228 score, laboratory parameters). Patients who received tocilizumab may have developed more  
229 severe disease during the course of their ICU stay, however, our institutional policies regarding  
230 tocilizumab included important exclusion criteria, including LFT abnormalities, suspected  
231 ongoing infection, and enrollment in a clinical trial (e.g. remdesivir). In light of these limitations,  
232 it appears unlikely that the group receiving tocilizumab was excessively enriched with the sickest  
233 patients and gives credence to the descriptive power of the severity of illness captured by  
234 APACHE II scoring. While the non-tocilizumab group did not have any patients with  
235 transplantation and all patients with history of transplantation were in the tocilizumab group,  
236 history of transplantation did not affect the outcomes. Furthermore, it should be noted that the  
237 mortality data herein should be considered preliminary, because some patients were still  
238 hospitalized at the time of this analysis and all outcomes were not known.

239 We did not restrict our definition to rely solely on microbiologic data but defined infection as:  
240 documented infection in the medical record and antibiotic therapy initiated and continued for >2  
241 days. This definition reflects real-world circumstances, as microbiologic identification of the  
242 causative organism is frequently not achieved in infections in the ICU, in particular for hospital-  
243 acquired and ventilator-acquired pneumonias (HAP, VAP). Furthermore, the IDSA/ATS  
244 guideline definitions of HAP and VAP do not rely on microbiologic data. Nonetheless, it is  
245 possible that our definition is too broad and may capture some patients who were treated for  
246 clinical deterioration due to COVID-19 rather than a secondary infection. However, our  
247 definition is similar to other studies where diagnoses are based on coding. Restriction to only  
248 microbiologically proven cases would likely miss a number of infections and may capture  
249 contaminants. While the numbers are small, the autopsy findings support the notion that bacterial  
250 pneumonia may be present even in absence of positive culture data.

251 Severe COVID-19 often elicits a strong inflammatory response with elevation in several  
252 cytokines, such as IL-6. This inflammatory phenotype shares clinical features with CAR-T cell-  
253 induced CRS and has led to the off-label use of tocilizumab for COVID-19. However, clinical  
254 similarity does not necessarily mean that changes seen in COVID-19 and CAR-T CRS are  
255 causally related and due to an overactive immune system. At least in part, the forceful immune  
256 response in COVID-19 may be adaptive and required for the anti-viral response. In our group of  
257 critically-ill COVID-19 patients, the use of tocilizumab was associated with an increase in  
258 infections. Our findings should raise physician awareness about the potential side effects of  
259 tocilizumab on pathogen clearance and development of secondary infections and additional risk  
260 vs. benefit discussions with patients and their families. It also calls for the urgent need to study  
261 all drugs including any immunosuppressive agents in randomized controlled trials to better  
262 understand their role in any hyperimmune response and on clearance of SARS-CoV-2 and other  
263 hospital-acquired pathogens, before their routine use is widely implemented.

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

### 264 5 REFERENCES

- 265 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
266 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.  
267 *Lancet*. 2020;395(10229):1054-62.
- 268 2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-  
269 19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-  
270 4.
- 271 3. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired  
272 immune and acute-phase responses in interleukin-6-deficient mice. *Nature*. 1994;368(6469):339-  
273 42.
- 274 4. Narazaki M, Kishimoto T. The Two-Faced Cytokine IL-6 in Host Defense and Diseases.  
275 *Int J Mol Sci*. 2018;19(11).
- 276 5. Lang VR, Engbrecht M, Rech J, Nusslein H, Manger K, Schuch F, et al. Risk of  
277 infections in rheumatoid arthritis patients treated with tocilizumab. *Rheumatology (Oxford)*.  
278 2012;51(5):852-7.
- 279 6. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, et al. Risk of  
280 serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis:  
281 a multidatabase cohort study. *Ann Rheum Dis*. 2019;78(4):456-64.
- 282 7. Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological  
283 and Small Molecule Targeted Immunomodulatory Therapies. *Clin Microbiol Rev*. 2020;33(3).
- 284 8. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of  
285 Interleukin 6 During Viral Infections. *Front Microbiol*. 2019;10:1057.
- 286 9. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-  
287 19 patients with tocilizumab. *Proc Natl Acad Sci U S A*. 2020;117(20):10970-5.
- 288 10. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the  
289 treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute  
290 respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev*.  
291 2020;19(7):102568.
- 292 11. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of  
293 tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. *Eur J Intern Med*.  
294 2020;76:36-42.
- 295 12. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single  
296 center experience. *J Med Virol*. 2020;92(7):814-8.
- 297 13. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy  
298 and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort  
299 study. *Eur J Intern Med*. 2020;76:43-9.
- 300 14. Mansournia MA, Geroldinger A, Greenland S, Heinze G. Separation in Logistic  
301 Regression: Causes, Consequences, and Control. *Am J Epidemiol*. 2018;187(4):864-70.
- 302 15. Fisher CJ, Jr., Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of  
303 septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF  
304 Receptor Sepsis Study Group. *N Engl J Med*. 1996;334(26):1697-702.
- 305 16. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF  
306 therapy and increased risk of infections. *Drug Healthc Patient Saf*. 2013;5:79-99.

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

### 307 6 Figures

308 **Figure 1. Laboratory data in tocilizumab and non-tocilizumab groups.** A. White blood cell  
309 (WBC) count, B. percent lymphocyte, C. absolute lymphocyte count, D. D-dimer, E. C-reactive  
310 protein and F. Ferritin levels on day 1 of admission to the ICU. There was no difference between  
311 non-tocilizumab (non-toci) and tocilizumab (toci) groups in laboratory data except for absolute  
312 lymphocyte count, which was lower in the tocilizumab group. ns: not significant.

313 **Figure 2. Postmortem histopathology of lungs from COVID-19 patients.** Low (100x) and  
314 high power (200x) images of lungs from patients who died due to COVID-19. A. Organizing  
315 hyaline membranes are seen in the lung which has pre-existing emphysema (100x). Higher  
316 power shows fibrin, fibroblasts and mononuclear cells incorporated into the alveolar walls  
317 (200x). B. There is diffuse alveolar damage with hyaline membranes lining alveoli (100x).  
318 Higher power shows minimal inflammation with only a few mononuclear cells (200x). C. There  
319 is extensive intra-alveolar inflammation (neutrophils) in an otherwise normal lung (100x). On  
320 higher power, there is minimal alveolar wall thickening by inflammatory cells (also mainly  
321 neutrophils on myeloperoxidase staining and only rare lymphocytes) (200x). D. Majority of the  
322 sections from this case show organizing intra-alveolar fibrin (100x). Several foci of acute

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

### 323 7 Tables

<b>Table 1. Co-morbidities and Infection outcomes</b>			
	<b>No tocilizumab (n=57)</b>	<b>Tocilizumab (n=54)</b>	<b>p value*</b>
<b>Patient characteristics and comorbidities</b>			
Age (Mean ± Standard Deviation)	61.8 ± 16.6	64.5 ± 13.6	0.347
APACHE II (Mean ± Standard Deviation)	15.65 ± 8.70	17.33 ± 5.68	0.078
<25	50	48	
≥25	7	6	0.848
Charlson Co-morbidity Index (CCI) (Mean ± Standard Deviation)	3.59 ± 3.82	3.82 ± 3.02	0.059
	<b>n (%)</b>	<b>n (%)</b>	
<b>CCI Categories</b>			
CCI=0	7 (12.3)	2 (3.7)	
CCI=1-2	17 (29.8)	19 (35.2)	
CCI=3-4	14 (24.6)	11 (20.4)	
CCI>=5	19 (33.3)	22 (40.7)	
Sex			0.009
Male	25 (43.9)	37 (68.5)	
Female	32 (56.1)	17 (31.5)	
Diabetes mellitus	24 (42.1)	21 (38.9)	0.730
Hypertension	38 (66.7)	36 (66.7)	1.000
ESRD	10 (17.5)	9 (16.7)	0.902
Obese (BMI>=30)	39 (68.4)	30 (55.6)	0.162
Overweight (BMI=25-30)	4 (7.0)	3 (5.6)	1.000
Any Cardiovascular Disease	10 (17.5)	13 (24.1)	0.375
Myocardial Infarction History	3 (5.2)	6 (11.1)	0.313
Congestive Heart Failure	9 (15.8)	6 (11.1)	0.471
Peripheral Vascular Disease	2 (3.5)	4 (7.4)	0.430
DVT/PE	2 (3.5)	6 (11.1)	0.155
Hyperlipidemia	9 (15.8)	11 (20.4)	0.530
Any Pulmonary Disease	15 (26.3)	9 (16.7)	0.466
Chronic Obstructive Pulmonary Disease	7 (12.3)	5 (9.3)	0.762
Stroke/TIA	9 (15.8)	6 (11.1)	0.582
Hemiplegia	5 (8.8)	1 (1.9)	0.207
Dementia	7 (12.3)	3 (5.6)	0.322
Any Connective Tissue Disorder	0 (0)	1 (1.9)	0.486
Any Liver Disease	2 (3.5)	0 (0)	0.496
Cancer	4 (7.0)	7 (13.0)	0.352
Transplantation	0 (0)	5 (9.3)	0.025
Substance abuse	0 (0)	1 (1.8)	0.486
Alcohol abuse	4 (7.0)	2 (3.7)	0.679
Smoking			0.846
Never	31 (54.4)	32 (59.3)	
Past use	22 (38.6)	18 (33.3)	
Current use	4 (7.0)	4 (7.4)	
Immunosuppressive agents	1 (1.8)	7 (13.0)	0.029
Corticosteroids	8 (14.0)	13 (24.1)	0.227
<b>Infection outcomes</b>			
Bacterial infections	16 (28.1)	26 (48.1)	0.029
Hospital/ventilator-acquired pneumonia	9 (15.8)	18 (33.3)	
Sepsis, other source or undefined	7 (12.3)	8 (14.8)	
Fungal infections	0	3 <sup>#</sup> (5.6)	0.112
Pneumonia	0	1 (1.9)	
Sinusitis	0	2 (3.7)	
Microbiological diagnosis	9 (15.8)	10 (18.5)	0.530

324 \*T-tests, Mann-Whitney U, Chi-Square, or Fisher Exact tests were used as appropriate. <sup>#</sup>One patient suffered from  
325 both fungal pneumonia and fungal sinusitis.

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

326

<b>Table 2. Clinical Outcomes</b>				
	<b>Discharged</b>	<b>Died</b>	<b>Still hospitalized</b>	<b>p value*</b>
<b>Tocilizumab</b>				<b>0.020</b>
Yes	18	19	17	
No	34	11	12	
<b>Steroids</b>				<b>0.098</b>
Yes	46	24	20	
No	6	6	9	
<b>Steroids and Tocilizumab</b>				<b>0.128</b>
Yes	3	4	6	
No	49	26	23	
<b>Transplantation</b>				<b>0.202</b>
Yes	1	1	3	
No	51	29	26	
<b>Immunosuppressive agents</b>				<b>0.250</b>
Yes	2	2	4	
No	50	28	25	

327

328

329

\*Chi-Square, or Fisher Exact tests were used as appropriate.

## IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

### 330 **8 Conflicts of Interest**

331 *The authors declare that the research was conducted in the absence of any commercial or*  
332 *financial relationships that could be construed as a potential conflict of interest.*

### 333 **9 Author Contributions**

334 GMM, LMK, DW, NP conceived ideas and design. GMM, LMK, DW, MG, EAM, JM, AH  
335 performed data collection. EAM, GMM, LMK, DW, MG, JM, AH, NP, DP performed data  
336 analysis and interpretation. Manuscript drafting and editing was done by GMM, LMK, DW,  
337 EAM, NP, DP.

### 338 **10 Funding**

339 This work was supported by the following grants: T32HL007605 (LMK), K99HL145113 (DW),  
340 and R01ES010524, and W81XWH-16-1-0711 (GMM)

### 341 **11 Acknowledgements**

342 A prior version of this manuscript was previously made available as a pre-print manuscript on  
343 *medRxiv* (doi: <https://doi.org/10.1101/2020.05.15.20103531>).



